retatrutide side effects phase 2 trial Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 🚨The first phase 3 retatrutide

In trials, people taking retatrutide lost an average of 24% of their body weight over 48 weeks, compared to around 15-17% with Wegovy (semaglutide) and 15-22% with Mounjaro (tirzepatide)

ROCHA, C

Patients in this study were randomized in a 1:1:2 ratio to receive retatrutide 9 mg, 12 mg, or placebo over a period of 80 weeks

In this article, we will take a closer look at the potential involvement between Adderall and low sex drive, seek to understand why this is the case, and propose practical solutions on how to determine the potential sexual side effects

The study authors couldnt determine whether the medication itself caused these outcomes, or whether theyre attributable to the underlying health conditions of the women taking it

Daytryp plans to offer retatrutide in the future as part of its mission to bring patients the latest proven therapies